A5030094794- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Immunodeficiency and Autoimmune Disorders
- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- Multiple Myeloma Research and Treatments
- Hematopoietic Stem Cell Transplantation
- Chronic Myeloid Leukemia Treatments
- Viral-associated cancers and disorders
- Glycosylation and Glycoproteins Research
- Monoclonal and Polyclonal Antibodies Research
- Advanced Breast Cancer Therapies
- Genomic variations and chromosomal abnormalities
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Protein Degradation and Inhibitors
- Retinoids in leukemia and cellular processes
- Peptidase Inhibition and Analysis
- Cancer Treatment and Pharmacology
- Neutropenia and Cancer Infections
- Cancer-related Molecular Pathways
- Immune Cell Function and Interaction
- Cancer Genomics and Diagnostics
- Histone Deacetylase Inhibitors Research
- HIV/AIDS drug development and treatment
- Drug Transport and Resistance Mechanisms
Skåne University Hospital
2016-2025
Lund University
2016-2025
Stem Cell Institute
2008-2021
Leukemia Research Foundation
2008-2021
Hudson Institute
2020
John Wiley & Sons (United States)
2020
Boston University
2019
Seattle University
2019
Getinge (Sweden)
2017
NHS Blood and Transplant
2017
Specific chromosomal abnormalities have been shown to affect the overall survival of patients with acute leukemia, but possibility that specific defects may influence course B-cell chronic lymphocytic leukemia (CLL) is controversial. We assessed this as follows: blood mononuclear cells from 433 CLL in five European centers were cultured mitogens, and banded metaphases studied.
Purpose APR-246 (PRIMA-1MET) is a novel drug that restores transcriptional activity of unfolded wild-type or mutant p53. The main aims this first-in-human trial were to determine maximum-tolerated dose (MTD), safety, dose-limiting toxicities (DLTs), and pharmacokinetics (PK) APR-246. Patients Methods was administered as 2-hour intravenous infusion once per day for 4 consecutive days in 22 patients with hematologic malignancies prostate cancer. Acute myeloid leukemia (AML; n = 7) cancer (n...
Patients with secondary acute myeloid leukemia (AML) often escape inclusion in clinical trials and thus, population‐based studies are crucial for its accurate characterization. In this first large study on AML, we studied AML an antecedent hematological disease (AHD‐AML) or therapy‐related (t‐AML) the Swedish Acute Leukemia Registry. The included 3,363 adult patients of which 2,474 (73.6%) had de novo 630 (18.7%) AHD‐AML, 259 (7.7%) t‐AML. Secondary differed significantly compared to respect...
Randomized trials of venetoclax plus anti-CD20 antibodies as first-line treatment in fit patients (i.e., those with a low burden coexisting conditions) advanced chronic lymphocytic leukemia (CLL) have been lacking. Download PDF the Research Summary. In phase 3, open-label trial, we randomly assigned, 1:1:1:1 ratio, CLL who did not TP53 aberrations to receive six cycles chemoimmunotherapy (fludarabine–cyclophosphamide–rituximab or bendamustine–rituximab) 12 venetoclax–rituximab,...
Abstract We present a strategy for detection of loss-of-heterozygosity and allelic imbalance in cancer cells from whole genome single nucleotide polymorphism genotyping data. Using dilution series tumor cell line mixed with its paired normal data generated on Affymetrix Illumina platforms, including tumor-normal samples tumors characterized by fluorescent situ hybridization, we demonstrate high sensitivity specificity the detecting both minute gross imbalances heterogeneous samples.
Abstract Background Illumina Infinium whole genome genotyping (WGG) arrays are increasingly being applied in cancer genomics to study gene copy number alterations and allele-specific aberrations such as loss-of-heterozygosity (LOH). Methods developed for normalization of WGG have mostly focused on diploid, normal samples. However, samples genomic may confound data interpretation. Therefore, we examined the effects conventionally used method when Results We demonstrate an asymmetry detection...